Share on StockTwits

Ariad Pharmaceuticals (NASDAQ:ARIA) Director Alexander J. Denner bought 850,000 shares of Ariad Pharmaceuticals stock in a transaction dated Friday, August 15th. The stock was purchased at an average cost of $5.83 per share, for a total transaction of $4,955,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 6.06 on Thursday. Ariad Pharmaceuticals has a 52 week low of $2.15 and a 52 week high of $23.00. The stock has a 50-day moving average of $5.7 and a 200-day moving average of $6.95. The company’s market cap is $1.133 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.01. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $13.65 million. During the same quarter in the previous year, the company posted ($0.37) earnings per share. The company’s revenue for the quarter was down 13.6% on a year-over-year basis. On average, analysts predict that Ariad Pharmaceuticals will post $-1.15 earnings per share for the current fiscal year.

A number of research firms have recently commented on ARIA. Analysts at Citigroup Inc. reiterated a “sell” rating on shares of Ariad Pharmaceuticals in a research note on Friday, August 8th. They now have a $5.00 price target on the stock, down previously from $7.00. Separately, analysts at JMP Securities cut their price target on shares of Ariad Pharmaceuticals from $8.00 to $7.00 in a research note on Thursday, August 7th. They now have a “market outperform” rating on the stock. Finally, analysts at Chardan Capital reiterated a “buy” rating on shares of Ariad Pharmaceuticals in a research note on Thursday, August 7th. Four research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

Receive News & Ratings for Ariad Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.